Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.

Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...

AbbVie has secured its fourth FDA approval for Vraylar, adding adjunctive therapy of major depressive disorder (MDD) to a list that includes schizophrenia and manic and depressive episodes in ...

As a measles outbreak causes dozens of illnesses in West Texas, it’s important to know how to identify signs of the illness – ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

Concomitant use of statins improved survival among people with cancer treated with immune checkpoint inhibitors, according to ...

On-demand video webcast now available here TAMPA, FL / ACCESS Newswire / February 19, 2025 /TuHURA Biosciences, Inc.

Alto Neuroscienc announced that the U.S. Patent and Trademark Office has granted U.S. Patent Number 12,226,375, with method claims pertaining ...

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

A digital therapeutic (DTx) for attention deficit hyperactivity disorder (ADHD) developed by Akili has been approved in Japan, where it will be sold by licensee Shionogi.

IntroductionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing ...